受体氨酸激酶信号传递涉及埃奇诺科克-宿主相互通信:在肝脏埃奇诺科克菌病中潜在的治疗标
Haijun Gao1,2, Zhuoma Bianba3, Xiaojin Mo2,3
1Chengdu Fifth People's Hospital (Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine; The Second Clinical Medical College), Chengdu 611130, China.
Tropical medicine and infectious disease
|August 28, 2024
概括
受体氨酸激酶 (RTK) 信号在严重的寄生虫疾病 - - 乙球菌病中过度激活. 氨酸激酶抑制剂 (TKIs) 通过向这种途径,显示出作为新型抗球菌病药物的前景.
科学领域:
- 寄生虫学和分子生物学
- 主体-寄生虫相互作用
- 药物发现 药物发现
背景情况:
- 由 Echinococcus granulosus 和 Echinococcus multilocularis 引起的 Echinococcosis 是一种危及生命的动物病,具有具有挑战性的治疗选择,包括 albendazole.
- 受体氨酸激酶 (RTK) 信号传递对宿主细胞功能至关重要,但其干扰与癌症和寄生虫疾病进展有关.
- 在 Echinococcus 寄生虫中存在 RTK 信号通路,但它们在宿主-寄生虫通信中的作用尚不清楚.
研究的目的:
- 调查RTK信号传递在 Echinococcus-宿主相互通信中的作用.
- 探索针对RTK信号传导的潜力,用于新球菌病治疗.
主要方法:
- 在宿主-寄生虫相互作用中对RTK信号传递的现有文献的审查.
- 分析研究的分析,调查氨酸激酶抑制剂 (TKI) 对 Echinococcus 寄生虫的影响.
- 关于TCI疗效和作用机制的体外和体外实验数据.
主要成果:
- 在 Echinococcus 感染期间,宿主 RTK 信号升级,促进了寄生虫的发展.
- 某些TKIs在体外和体内表现出对 Echinococcus 种类的显著寄生静止作用.
- TKIs的功能是通过降低寄生虫或宿主内的关键RTK信号分子的调节.
结论:
- RTK信号传递代表了球菌病的一个有前途的治疗标.
- 氨酸激酶抑制剂 (TKIs) 显示出作为新型抗赤道球菌病药物的潜力.
- 进一步的研究是有必要的,以开发基于TKI的治疗 echinococcosis.
关键词:
埃奇诺科克 (Echinococcus metacestodes) 是一种有机植物.药物目标是药物目标.埃奇诺科科菌病 (echinococcosis) 是一种受体氨酸激酶的受体.氨酸激酶抑制剂 氨酸激酶抑制剂更多相关视频
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.2K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.2K
Receptor Tyrosine Kinases
12.5K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Enzyme-linked Receptors
77.7K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


